Johnson & Johnson (JNJ) Holdings Reduced by Guggenheim Capital LLC
Guggenheim Capital LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,058,389 shares of the company’s stock after selling 30,568 shares during the quarter. Johnson & Johnson comprises about 0.3% of Guggenheim Capital LLC’s portfolio, making the stock its 16th biggest holding. Guggenheim Capital LLC’s holdings in Johnson & Johnson were worth $135,635,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. TT International lifted its position in shares of Johnson & Johnson by 254.1% during the first quarter. TT International now owns 136,518 shares of the company’s stock worth $15,930,000 after purchasing an additional 97,969 shares in the last quarter. Eagle Global Advisors LLC lifted its position in shares of Johnson & Johnson by 1.6% during the first quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock worth $9,927,000 after purchasing an additional 1,221 shares in the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Johnson & Johnson by 1.9% during the first quarter. Great West Life Assurance Co. Can now owns 3,784,116 shares of the company’s stock worth $485,495,000 after purchasing an additional 72,159 shares in the last quarter. Trexquant Investment LP lifted its position in shares of Johnson & Johnson by 28.2% during the first quarter. Trexquant Investment LP now owns 22,542 shares of the company’s stock worth $2,889,000 after purchasing an additional 4,959 shares in the last quarter. Finally, NuWave Investment Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $680,000. 71.53% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson stock opened at $136.87 on Friday. The company has a market capitalization of $364.50 billion, a price-to-earnings ratio of 17.42, a P/E/G ratio of 2.07 and a beta of 0.69. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
JNJ has been the topic of several analyst reports. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a report on Friday, May 18th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. ValuEngine cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, July 13th. Finally, Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $142.34.
In other news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.